Floatz logo

(+)-VINCRISTINE

Leukemia, Lymphoblastic, Acute, Philadelphia-Positive

Novartis PharmaceuticalsSmall moleculePhase 3Active
B
63/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
81/ 100

Competitive context

9 Active assets in the Leukemia, Lymphoblastic, Acute, Philadelphia-Positive cohort.

Asset / SponsorPhaseRating
Cytosin-Arabinosid
Novartis Pharmaceuticals
Phase 3BB
Dasatinib
SWOG Cancer Research Network
Phase 3BB
DEXAMETHASONE
Novartis Pharmaceuticals
Phase 3BB
Blinatumomab
Novartis Pharmaceuticals
Phase 3BB
Olverembatinib
Institute of Hematology & Blood Diseases Hospital, China
Phase 3BB

View all 13 →

Same molecule, other indications

(+)-VINCRISTINE is also rated in:

anaplastic large cell lymphomaDormant
BBB
Indicative ·
78 / 100
View asset →
mycosis fungoidesDormant
BBB
Indicative ·
78 / 100
View asset →
adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
77 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →